[ Price : $8.95]
CDER issues its annual report for FY 2009 highlighting its work on the pandemic flu.[ Price : $8.95]
Utah files a state false claims suit against GlaxoSmithKline for allegedly marketing Avandia as a new wonder drug to treat Type 2 ...[ Price : $8.95]
Editor Jim Dickinson critiques a Wall Street Journal critique of outsourced FDA management training contracts and suggests the con...[ Price : $8.95]
An FDA review summary of Human Genome Sciences' BLA for lupus therapy Benlysta (belimumab) shows that the serious risks were great...[ Price : $8.95]
Centocor submits a second 2010 sBLA to FDA seeking to broaden the indication for its Simponi.[ Price : $8.95]
Johnson & Johnson says it is trying to resolve potential federal civil and criminal charges relating to Risperdal marketing.[ Price : $8.95]
CDER director Janet Woodcock makes the case for a new federal research infrastructure to involve community doctors in comparative ...[ Price : $8.95]
NephRx begins a Phase 1 clinical trial of its lead compound NX001, a kidney growth factor peptide under development for preventing...